Caleco Pharma Corp.
OTC Bulletin Board : CAEH
FRANKFURT : T3R

Caleco Pharma Corp.

December 07, 2009 08:30 ET

Caleco Pharma Corp. Announces Negotiations to Form a Strategic Alliance With Rearden Health Partners

BELLINGHAM, WASHINGTON--(Marketwire - Dec. 7, 2009) - (OTCBB:CAEH)(FRANKFURT:T3R)(WKN:A0N9Y0); www.calecopharmacorp.com) Caleco Pharma Corp. (the "Company") is pleased to announce that it has entered into negotiations to form a strategic alliance with Rearden Health Partners, a healthcare media and technology firm that designs proprietary health education, marketing and communications products and services used to support healthcare product development and commercialization. A co-founder of Rearden Health Partners, Jim Metropoulos, M.D., is also a member of the Company's Product Development Advisory Board. Dr. Metropoulos has extensive experience in the healthcare communications and consulting industry, including serving as a senior executive of various healthcare services companies over the past 18 years.

"Rearden Health Partners and Caleco Pharma will utilize proprietary communications products, services and strategies in the development of Caleco's growing product pipeline. We are quite impressed with Caleco's ability to identify products for in licensing and development and with their innovative approaches to market development and sales. We believe Rearden Health Partners' product development and commercialization expertise is a very good fit with Caleco Pharma's unique approach to creating a diverse healthcare products incubator." said Dr. Metropoulos, Co-Founder of Rearden Health Partners.

About Caleco Pharma Corp.

The Company is focused on the ongoing research and development of its broad pipeline of over-the-counter and prescription medications including its proprietary "Liver Health Formula" technology designed to treat moderate to severe liver maladies, including Hepatitis C viral infection. In addition the Company is developing Food Supplements and over-the-counter Dermatological Products based on the active ingredients found in the Liver Health Formula. To date, the Company's intellectual property covering the Liver Health Formula comprises of patent applications in the United States, Europe and Canada and four European Drug Master File applications.

Caleco Pharma Corp. shares are traded in the United States on the OTC Bulletin Board (OTCBB:CAEH) and in Germany on the Frankfurt Stock Exchange (WKN: A0N9Y0/ Symbol: T3R.FSE).

This press release may contain, in addition to historic information, forward-looking statements. These statements may involve known and unknown risks and uncertainties and other factors that may cause the actual results to be materially different from the results implied herein. In particular, there are no assurances that: (i) the Company's negotiations will result in the formation of a strategic alliance with Reardon Health Partners; (ii) the United States Patents and Trademarks Office will grant the Company a patent in connection with its current patent applications; (iii) the Company will be able to manufacture and produce its products or that its products will be effective; or (iv) it will be able to carry out any pre-clinical or clinical trials of its products. Readers are cautioned not to place undue reliance on the forward-looking statements made in this press release.

Caleco Pharma Corp.

John Boschert, President

Contact Information